BIOS Capital Management, LP
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), BIOS Capital Management, LP reported 6 stock positions worth $41.7 million. Its top holding was Actuate Therapeutics (ACTU) at 36.9% of the portfolio, followed by Opus Genetics (IRD, 36.3%) and Cognition Therapeutics (CGTX, 16.6%). Compared with Q1 2026, it added to 1 and reduced 2. The biggest buy was Rein Therapeutics (RNTX, shares +50%) and the biggest sale IN8BIO (INAB, shares −52%).
- Most Recent 13F
- Q2 2026
- Location
- Fort Worth, TX
- CIK
- 0001813845
- Portfolio Value
- $41.7M (Q2 2026)
- SEC Filing
- 0001813845-26-000004 ↗ filed Aug 14, 2026
Holdings Value
Holdings 6 stocks · $41.7M
| ACTU Actuate Therapeutics Inc. | 36.90% | 10,049,996 | $15.4M | No change |
| IRD Opus Genetics Inc. | 36.33% | 3,683,429 | $15.1M | No change |
| CGTX Cognition Therapeutics Inc. | 16.56% | 6,000,000 | $6.9M | No change |
| RNTX Rein Therapeutics Inc. | 7.44% | 2,982,375 | $3.1M | Add +50.4% |
| LTRN Lantern Pharma Inc. | 2.50% | 249,397 | $1.0M | Reduce -71.2% |
| INAB IN8BIO Inc. | 0.27% | 80,957 | $114K | Reduce -51.8% |
Portfolio Sells Q1 2026 → Q2 2026
Portfolio Buys Q1 2026 → Q2 2026
| RNTX Rein Therapeutics Inc. | Add +50.4% | 7.44% | +2.57 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 6 | $41.7M | ACTU, IRD, CGTX, RNTX, LTRN |
| Q1 2026 | 6 | $52.9M | ACTU, IRD, CGTX, RNTX, LTRN |
| Q4 2025 | 6 | $82.6M | ACTU, CGTX, IRD, LTRN, RNTX |
| Q3 2025 | 6 | $88.9M | ACTU, CGTX, IRD, LTRN, RNTX |
| Q2 2025 | 6 | $72.6M | ACTU, IRD, LTRN, RNTX, CGTX |
| Q1 2025 | 6 | $79.2M | ACTU, LTRN, RNTX, CGTX, INAB |
| Q4 2024Amended | 6 | $94.1M | ACTU, CGTX, RNTX, LTRN, INAB |